Vertex Pharmaceuticalsの空売り状況は、投資家がVertex Pharmaceuticalsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Vertex Pharmaceuticals (NASDAQ:VRTX) 株価情報, 空売り情報

Vertex Pharmaceuticals

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Analyst Ratings

VRTX

Vertex Pharmaceuticals（NASDAQ:VRTX）に14人のアナリストが過去3か月間で分析を行ったところ、その視点は強気から弱気まで多様なものとなった。

14人のアナリスト分析からVertexの市場動向を追う

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals Inc

Whales with a lot of money to spend have taken a noticeably bearish stance on Vertex Pharmaceuticals.
Looking at options history for Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) we detected 8 trades.
If we consider the specifics of each trade, it is accurate to state that 37% of the investors opened trades with bullish expectations and 50% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $266,785 and 3, calls, for a total amount of $162,840.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $420.0 to $550.0 for Vertex Pharmaceuticals during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Vertex Pharmaceuticals's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Vertex Pharmaceuticals's whale trades within a strike price range from $420.0 to $550.0 in the last 30 days. 
<h3>Vertex Pharmaceuticals Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731961818_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$15.8</td>
<td>$14.6</td>
<td>$15.0</td>
<td>$450.00</td>
<td>$99.0K</td>
<td align="right">500</td>
<td align="right">66</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$46.8</td>
<td>$41.8</td>
<td>$44.0</td>
<td>$440.00</td>
<td>$88.0K</td>
<td align="right">439</td>
<td align="right">20</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$15.3</td>
<td>$13.6</td>
<td>$15.0</td>
<td>$450.00</td>
<td>$51.0K</td>
<td align="right">500</td>
<td align="right">100</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$50.9</td>
<td>$44.8</td>
<td>$46.02</td>
<td>$420.00</td>
<td>$46.0K</td>
<td align="right">0</td>
<td align="right">10</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$2.95</td>
<td>$2.65</td>
<td>$2.65</td>
<td>$550.00</td>
<td>$40.2K</td>
<td align="right">69</td>
<td align="right">152</td>
</tr>
</tbody>
</table>

<h3>About Vertex Pharmaceuticals</h3>
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Following our analysis of the options activities associated with Vertex Pharmaceuticals, we pivot to a closer look at the company's own performance.
<h3>Vertex Pharmaceuticals's Current Market Status</h3>
<ul>
<li>With a volume of 565,702, the price of VRTX is up 0.06% at $466.0. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 77 days.</li>
</ul>
<h3>Expert Opinions on Vertex Pharmaceuticals</h3>
In the last month, 5 experts released ratings on this stock with an average target price of $492.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from Scotiabank continues to hold a Sector Perform rating for Vertex Pharmaceuticals, targeting a price of $486. 
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Vertex Pharmaceuticals with a target price of $503. 
&#x2A; Maintaining their stance, an analyst from Oppenheimer continues to hold a Outperform rating for Vertex Pharmaceuticals, targeting a price of $540. 
&#x2A; An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $480. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Sector Perform rating on Vertex Pharmaceuticals with a target price of $451. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Vertex Pharmaceuticals, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

A Closer Look at Vertex Pharmaceuticals's Options Market Dynamics

WIIM

Shares of pharmaceutical companies are trading lower After President-elect Trump nominated Robert F. Kennedy Jr. to lead the HHS.

<a href="https://www.mckesson.com/about-mckesson/newsroom/press-releases/2024/inspirogene-by-mckesson-partners-with-vertex-to-expand-distribution-options-for-casgevy/" title="https://www.mckesson.com/about-mckesson/newsroom/press-releases/2024/inspirogene-by-mckesson-partners-with-vertex-to-expand-distribution-options-for-casgevy/">https://www.mckesson.com/about-mckesson/newsroom/press-releases/2024/inspirogene-by-mckesson-partners-with-vertex-to-expand-distribution-options-for-casgevy/</a>

Biotech

News

General

InspiroGene by McKesson Partners With Vertex To Expand Distribution Of CASGEVY, The First FDA-Approved CRISPR Gene-Editing Therapy For Sickle Cell Disease And β-Thalassemia

Citigroup analyst Geoff Meacham initiates coverage on Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Buy rating and announces Price Target of $575.

Price Target

Initiation

Citigroup Initiates Coverage On Vertex Pharmaceuticals with Buy Rating, Announces Price Target of $575

Canaccord Genuity analyst Whitney Ijem maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Sell and raises the price target from $361 to $408.

Canaccord Genuity Maintains Sell on Vertex Pharmaceuticals, Raises Price Target to $408

Scotiabank analyst Greg Harrison maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Sector Perform and raises the price target from $480 to $486.

Scotiabank Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $486

Investors with a lot of money to spend have taken a bullish stance on Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with VRTX, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 19 uncommon options trades for Vertex Pharmaceuticals.
This isn't normal.
The overall sentiment of these big-money traders is split between 47% bullish and 42%, bearish.
Out of all of the special options we uncovered, 2 are puts, for a total amount of $201,378, and 17 are calls, for a total amount of $1,435,690.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $370.0 and $700.0 for Vertex Pharmaceuticals, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Vertex Pharmaceuticals's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Vertex Pharmaceuticals's significant trades, within a strike price range of $370.0 to $700.0, over the past month.
<h3>Vertex Pharmaceuticals Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730831527_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$34.4</td>
<td>$32.5</td>
<td>$32.5</td>
<td>$490.00</td>
<td>$396.5K</td>
<td style="text-align: right;">348</td>
<td style="text-align: right;">135</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$33.5</td>
<td>$29.2</td>
<td>$31.5</td>
<td>$490.00</td>
<td>$245.7K</td>
<td style="text-align: right;">348</td>
<td style="text-align: right;">213</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$85.0</td>
<td>$81.4</td>
<td>$85.0</td>
<td>$400.00</td>
<td>$170.0K</td>
<td style="text-align: right;">79</td>
<td style="text-align: right;">20</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$10.4</td>
<td>$6.4</td>
<td>$8.87</td>
<td>$450.00</td>
<td>$169.8K</td>
<td style="text-align: right;">36</td>
<td style="text-align: right;">196</td>
</tr>
<tr>
<td>VRTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$57.8</td>
<td>$56.1</td>
<td>$56.1</td>
<td>$480.00</td>
<td>$123.4K</td>
<td style="text-align: right;">45</td>
<td style="text-align: right;">22</td>
</tr>
</tbody>
</table>

<h3>About Vertex Pharmaceuticals</h3>
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Following our analysis of the options activities associated with Vertex Pharmaceuticals, we pivot to a closer look at the company's own performance.
<h3>Vertex Pharmaceuticals's Current Market Status</h3>
<ul>
<li>Trading volume stands at 647,404, with VRTX's price up by 4.99%, positioned at $496.38.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 90 days.</li>
</ul>
<h3>Expert Opinions on Vertex Pharmaceuticals</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $500.2.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on Vertex Pharmaceuticals, which currently sits at a price target of $503. 
&#x2A; An analyst from Oppenheimer has decided to maintain their Outperform rating on Vertex Pharmaceuticals, which currently sits at a price target of $540. 
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Buy rating on Vertex Pharmaceuticals with a target price of $541. 
&#x2A; An analyst from Scotiabank downgraded its action to Sector Perform with a price target of $480. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Sector Perform rating on Vertex Pharmaceuticals with a target price of $437. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Vertex Pharmaceuticals, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Spotlight on Vertex Pharmaceuticals: Analyzing the Surge in Options Activity

Wall Street rallied on Tuesday as improved investor sentiment aligned with millions of Americans casting their votes <a href="https://www.benzinga.com/topic/2024-election">for the 47th president.</a>
Betting markets leaned slightly toward Donald Trump, with CFTC-regulated Kalshi placing Trump's win probability at 56% compared to Kamala Harris's 44%.
National polls show a close contest, with the latest New York Times/Siena College poll indicating both candidates tied at 48% in the popular vote.
The S&amp;P 500 climbed 1.2%, while the tech-focused Nasdaq 100 surged 1.5%, marking its strongest one-day increase in nearly a month. 
All 11 sectors of the S&amp;P 500 experienced gains, with consumer discretionary stocks outperforming. Small caps also joined the rally, with the Russell 2000 index gaining 1.1%.
Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) led the S&amp;P 500, with shares soaring after the artificial intelligence company surpassed quarterly earnings estimates and provided strong guidance.
In macroeconomic news, U.S. services sector activity hit over two-year highs <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41750522/us-services-sector-gauge-rises-more-than-expected-to-over-2-year-highs-as-employm">in October, outperforming expectations</a>.
Treasury yields increased by 5 basis points, while the dollar declined for a second consecutive session.
Gold edged up 0.3%, hovering near record highs, and oil prices gained 1.2% after a 3.2% surge on Monday.
Crypto sentiment was strong as well, with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) jumping 4.5% to over $70,000 and Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) spiking 12%.
Read also: <a href="https://www.benzinga.com/markets/24/11/41741466/if-trump-and-republicans-sweep-dollar-may-climb-7-but-harris-win-could-bring-5-drop-says-jpmorgan">If Trump And Republicans Sweep, Dollar May Climb 7% — But Harris Win Could Bring 5% Drop, Says JPMorgan</a>
<h3 class="wp-block-heading">Tuesday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,259.62</td>
<td>1.5%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,779.38</td>
<td>1.2%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,244.40</td>
<td>1.1%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>42,191.93</td>
<td>1.0%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:30 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent110424&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 1.1% to $575.87.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;rose 0.9% to $421.79.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) soared 1.4% to $492.61.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 1.1% to $222.47.</li>
<li>The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, rising 1.7%. The Materials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, up 0.4%.</li>
</ul>
<h3 class="wp-block-heading">Monday&#8217;s Stock Movers</h3>
Stocks reacting to earnings reports included: 
<ul>
<li>Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), up 4.8%</li>
<li>Palantir Technologies Inc., up 22.8%</li>
<li>NXP Semiconductors NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>), down 6.8%</li>
<li>Diamondback Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>), down 1.6%</li>
<li>American International Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>), down 2.3%</li>
<li>Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), down 0.5%</li>
<li>Apollo Global Management Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>), up 6.2%</li>
<li>Emerson Electric Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>), up 6.8%, </li>
<li>Marathon Petroleum Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>), up 3.9%, </li>
<li>Cummins Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>), up 8.8%, </li>
<li>Targa Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>), 4.7%,</li>
<li>YUM! Brands, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUM#NYSE">YUM</a>), up 2.5%, </li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41746843/bond-market-fear-gauge-soars-to-1-year-high-ahead-of-us-election-results-bond-vigil">Bond Market Fear Gauge Soars To 1-Year High Ahead Of US Election Results: &#8216;Bond Vigilantes Have Been Voting Early&#8217;</a></li>
</ul>
Photo via Shutterstock.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Large Cap

Macro Economic Events

Bonds

Broad U.S. Equity ETFs

Commodities

Politics

Economics

Tech

ETFs

$BTC

$DOGE

SPDR Dow Jones Industrial Average ETF Trust

FANG

ILMN

NXPI

PLTR

TRGP

Select Sector SPDR-Consumer Discretionary

YUMC

Wall Street Rallies On Election Day, Palantir Skyrockets, Bitcoin Tops $70,000: What's Driving Markets Tuesday?

UBS analyst Colin Bristow maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Buy and raises the price target from $562 to $586.

UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $586

Cantor Fitzgerald analyst Olivia Brayer reiterates Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Overweight and maintains $480 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Vertex Pharmaceuticals, Maintains $480 Price Target

RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Sector Perform and raises the price target from $437 to $451.

RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $451

JP Morgan analyst Jessica Fye maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Overweight and lowers the price target from $510 to $503.

JP Morgan Maintains Overweight on Vertex Pharmaceuticals, Lowers Price Target to $503

Vertex Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 product revenue guidance above estimates. Also, Morgan Stanley maintained an Equal-Weight rating on the stock and raised its price target from $473 to $476.

Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $495.09, a high estimate of $600.00, and a low estimate of $425.00. Witnessing a positive shift, the current average has risen by 1.47% from the previous average price target of $487.90.
<img src="https://www.benzinga.com/files/images/story/2024/1730815318_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Vertex Pharmaceuticals among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$476.00</td>
<td>$473.00</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$540.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$600.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Colin Bristow</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$562.00</td>
<td>$477.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$480.00</td>
<td>-</td>
</tr>
<tr>
<td>Ying Huang</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$541.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$437.00</td>
<td>$425.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$480.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$425.00</td>
<td>$431.00</td>
</tr>
<tr>
<td>Matthew Harrison</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$474.00</td>
<td>$462.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$431.00</td>
<td>$431.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Vertex Pharmaceuticals. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Vertex Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Vertex Pharmaceuticals's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Vertex Pharmaceuticals's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/VRTX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Vertex Pharmaceuticals analyst ratings.</a>
<h2>About Vertex Pharmaceuticals</h2>
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
<h3>Vertex Pharmaceuticals: Financial Performance Dissected</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Over the 3 months period, Vertex Pharmaceuticals showcased positive performance, achieving a revenue growth rate of 6.11% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Vertex Pharmaceuticals's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -135.83%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Vertex Pharmaceuticals's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -21.57% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Vertex Pharmaceuticals's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -16.32%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.06, Vertex Pharmaceuticals adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Assessing Vertex Pharmaceuticals: Insights From 11 Financial Analysts

Morgan Stanley analyst Matthew Harrison maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Equal-Weight and raises the price target from $473 to $476.

Morgan Stanley Maintains Equal-Weight on Vertex Pharmaceuticals, Raises Price Target to $476

Guidance

Vertex Pharmaceuticals Sees FY 2024 Product Revenue $10.8B-$10.9B Vs $10.749B Est

Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) reported quarterly earnings of $4.38 per share which beat the analyst consensus estimate of $4.14 by 5.8 percent. The company reported quarterly sales of $2.77 billion which beat the analyst consensus estimate of $2.72 billion by 1.78 percent. This is a 11.59 percent increase over sales of $2.48 billion the same period last year.

Earnings

Earnings Beats

Vertex Pharmaceuticals Q3 2024 Adj EPS $4.38 Beats $4.14 Estimate, Sales $2.77B Beat $2.72B Estimate

The U.S. stock market struggled to gain momentum on Monday as investors remained cautious ahead of <a href="https://www.benzinga.com/topic/election-day">Election Day on Tuesday</a>. 
Vice President Kamala Harris holds a 1-point lead over ex-President Donald Trump, according to the New York Times national polling average; she has a 4-point lead among likely voters nationally, <a href="https://maristpoll.marist.edu/polls/u-s-presidential-contest-november-2024/">according to the latest PBS News/NPR/Marist poll</a>.
Betting markets, as tracked by the CFTC-regulated Kalshi, favor a Trump win at a 53% chance, <a href="https://www.benzinga.com/general/politics/24/11/41702729/harris-surges-in-prediction-markets-nabs-kalshi-lead-with-just-three-days-to-go">but with diminishing odds</a> compared to previous weeks. Also, the betting odds are susceptible to wild swings from so-called "whale" bettors, including one individual on Polymarket <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41463756/polymarket-to-review-user-base-in-light-of-whales-betting-millions-on-trump-election-win" target="_blank" rel="noreferrer noopener">who spent as much as</a> $43 million on a Trump victory.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41717129/polymarkets-all-time-leading-trader-bets-over-500-000-on-kamala-harris-slams-nate-silver-f">Polymarket&#8217;s All-Time Leading Trader Bets Over $500,000 On Kamala Harris, Slams Nate Silver For Including &#8216;Fake Poll&#8217; Data In Model</a>
&#8220;Neither candidate holds a meaningful edge in enough states to win 270 electoral votes. In the history of modern polling, there's never been a race where the final polls showed such a close contest,&#8221; said Nate Cohn, chief political analyst for the New York Times. 
The S&amp;P 500 slipped 0.2%, while the Dow dropped 0.6%, hitting its lowest intraday level since mid-September. In contrast, small-cap stocks in the Russell 2000 outperformed, rising 1%. The Nasdaq 100 also retreated, dipping below the 20,000 mark.
Treasury yields fell by nearly 10 basis points as investors scaled back positions linked to Trump&#8217;s inflationary policies, such as high tariffs and more expansionary fiscal measures. The dollar also weakened, down 0.5%.
The increasing likelihood of a Harris victory gave a boost to solar and renewable energy stocks, with the Invesco Solar ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAN#NYSE">TAN</a>) climbing 3.6%. 
Oil and gas stocks also gained, as crude prices surged 3% after OPEC+ postponed an anticipated production hike. Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) jumped 3%, marking its largest single-day gain since late June.
Gold held steady at $2,740, while Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) fell over 1%, dropping below $68,000.
<h3 class="wp-block-heading">Monday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,230.95</td>
<td>1.0%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,715.31</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,978.22</td>
<td>-0.3%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>41,807.92</td>
<td>-0.6%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:45 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent110424&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.1% to $570.22.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;fell 0.5% to $418.44.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 0.2% to $486.77.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) rose 1.1% to $221.27.</li>
<li>The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, rising 1.7%. The Utilities Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) lagged, down 1.5%.</li>
</ul>
<h3 class="wp-block-heading">Monday&#8217;s Stock Movers</h3>
Stocks reacting to earnings reports included: 
<ul>
<li>Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>), down 3.9%, </li>
<li>Constellation Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NYSE">CEG</a>), down 10.5%, </li>
<li>Marriott International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>), down 1.8%, </li>
<li>Fidelity National Information Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>), down 0.4%, </li>
<li>Public Service Enterprise Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEG#NYSE">PEG</a>), down 5.9%, </li>
<li>TPG Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>), down 5.5%. </li>
<li>Fox Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOX#NASDAQ">FOX</a>), up 3.7%, </li>
<li>YUM China Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YUMC#NYSE">YUMC</a>), up 7.9%, </li>
<li>Loews Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/L#NYSE">L</a>), down 4.8%, </li>
</ul>
Stocks slated to report earnings after the close are Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>), NXP Semiconductors NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>), Diamondback Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>), American International Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIG#NYSE">AIG</a>), Illumina Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), Hologic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLX#NASDAQ">HOLX</a>) and Astera Labs Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>).
Now Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41702887/harris-takes-lead-in-red-state-iowa-in-shock-poll">Harris Takes Lead In Red State Iowa In Shock Poll</a></li>
</ul>
Image: Shutterstock

Mid Cap

ALAB

HOLX

Wall Street Struggles Ahead Of Election Day, Energy Sector Outperforms, Solar Stocks Rise: What's Driving Markets Monday?

Vertex Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) will be reporting its third-quarter earnings on Monday. Wall Street expects $4.14 in EPS and $2.72 billion in revenues as the company reports<a href="https://www.benzinga.com/calendars/earnings?tickers=VRTX" target="_blank" rel="noreferrer noopener"> after market hours</a>.
Jim Cramer isn't holding back on Vertex stock <a href="https://www.benzinga.com//node/41652163">calling it a buy</a> and lauding its work as "doing the lord&#8217;s work" on CNBC's Mad Money Lightning Round. Cramer's endorsement adds to investor intrigue as Vertex prepares to release its third-quarter earnings. The stock is up 22.13% over the past year and 14.65% YTD.
Let&#8217;s look at what the charts indicate for Vertex stock and how the stock currently maps against Wall Street estimates.
Read Also: <a href="https://www.benzinga.com/news/24/11/41705158/cathie-wood-says-trumps-ideas-on-eliminating-income-tax-and-imposing-tariffs-brings-back-vibes-of-ea">Cathie Wood Says Trump&#8217;s Ideas On Eliminating Income Tax And Imposing Tariffs Brings Back Vibes Of &#8216;Early Days Of Our Country&#8217;</a>
<h2 class="wp-block-heading">Vertex Chart Faces A Strongly Bearish Trend Ahead Of Q3 Earnings&#8230;</h2>
Vertex stock currently faces a strongly bearish trend, with its $471.12 share price trailing its five, 20 and 50-day Exponential Moving Averages (EMA). 
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110424&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="628" height="455" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/04083044/Screenshot-2024-11-04-at-5.45.49-PM.png" alt="" class="wp-image-627826" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/04083044/Screenshot-2024-11-04-at-5.45.49-PM.png 628w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/04083044/Screenshot-2024-11-04-at-5.45.49-PM-300x217.png 300w" sizes="(max-width: 628px) 100vw, 628px" /></a></figure>
<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110424&amp;t=be2bearmibe3na1" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
This bearish momentum is reinforced as VRTX trades below key short-term Simple Moving Averages (SMA): the eight-day SMA at $473.57, the 20-day SMA at $475.65, and the 50-day SMA at $474.24—all signaling bearish pressure.
However, a longer-term bullish undertone is evident, with the 200-day SMA at $450.72 suggesting support. 
The Moving Average Convergence Divergence (MACD) indicator sits at 0.39, providing a bullish signal, while the Relative Strength Index (RSI) at 47.44 hints at balanced momentum. Despite the short-term bearish setup, these mixed signals indicate slight buying pressure that could support VRTX in the long run.
<h2 class="wp-block-heading">Yet Vertex Analysts See 22% Upside</h2>
Ratings &amp; Consensus Estimates:<a href="https://www.benzinga.com/quote/VRTX/analyst-ratings" target="_blank" rel="noreferrer noopener"> The consensus analyst rating</a> on Vertex stock stands at a Buy with a price target of $502.08. The latest analyst ratings from Oppenheimer, HC Wainwright &amp; Co. and UBS in October, set an average price target of $567.33 for Vertex stock, suggesting a 22.33% upside.
With mixed technical indicators, Vertex's third quarter results could be the deciding factor in this tug-of-war between Cramer's confidence and the bearish charts. As Cramer's bullish call sets the tone, all eyes are on Vertex to see if its earnings report can deliver the performance investors—and the charts—are waiting for.
VRTX Price Action: Vertex stock closed the trading day Friday at $472.12, down 1.02%.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/10/41584466/these-10-stocks-were-the-best-s-p-500-performers-in-2017-when-trump-was-president-will-history-r">These 10 Stocks Were The Best S&amp;P 500 Performers In 2017 When Trump Was President: Will History Repeat Itself?</a></li>
</ul>
Photo: Shutterstock

Health Care

Technicals

Previews

Trading Ideas

Jim Cramer Says Vertex Doing 'Lord's Work': Can Q3 Earnings Outshine Bearish Charts?

On CNBC's &#8220;Mad Money Lightning Round,&#8221; Jim Cramer said Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) is a buy. &#8220;This company is<a href="https://www.benzinga.com/quote/VRTX/analyst-ratings"> doing the lord's work,&#8221; he added.</a>
On Wednesday, Oppenheimer analyst Hartaj Singh maintained Vertex Pharmaceuticals with an Outperform and lowered the price target from $550 to $540.
CME Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CME#NASDAQ">CME</a>) is a &#8220;strong buy,&#8221; Cramer said. &#8220;It is one of the most consistent, great companies.&#8221;
On Oct. 23, CME reported quarterly earnings of $2.68 per share which beat the analyst consensus estimate of $2.65 per share. The company reported quarterly sales of $1.584 billion which beat the analyst consensus estimate of $1.579 billion.
The Mad Money host recommended buying T. Rowe Price Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TROW#NASDAQ">TROW</a>). &#8220;I think it's such a great company,&#8221; he added.
On Oct. 16, T. Rowe Price announced the appointment of Ben Riley to Head of Insurance.
&#8220;Enough with the selling&#8221; of Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>), Cramer said.
Micron announced changes to its Board of Directors on Wednesday. Micron said Robert (Bob) Switz, its current Board Chair, will retire on Jan. 16, 2025, while the board approved the appointment of Micron&#8217;s President and CEO, Sanjay Mehrotra, to serve as Board Chair.
Price Action:
<ul>
<li>Vertex Pharmaceuticals shares gained 1% to settle at $475.08 on Wednesday.</li>
<li>CME Group shares rose 0.1% to close at $227.26 on Wednesday.</li>
<li>T. Rowe Price shares fell 0.5% to settle at $111.81 during the session.</li>
<li>Micron fell 3.8% to settle at $104.08 on Wednesday.</li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41622545/wall-streets-most-accurate-analysts-spotlight-on-3-risk-off-stocks-delivering-high-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Risk Off Stocks Delivering High-Dividend Yields</a></li>
</ul>
Image: Shutterstock

Media

TROW

Jim Cramer: This Financial Stock Is 'One Of The Most Consistent, Great Companies'

Gilead, Vertex initiated as new big biotech buys at Citi

Vertex Pharmaceuticals Incorporated (VRTX) Guggenheim Inaugural Healthcare Innovation Conference (Transcript)

Large pharmas, biotechs down as industries grapple with RFK Jr. at HHS

Top 10 most expensive stocks (only 1 gets a Quant Sell)

Zoetis: This Beautifully Boring, Slow-Growing Compounder Is A Buy

Tracking Tweedy Browne Portfolio - Q3 2024 Update

Vertex Pharmaceuticals Incorporated (VRTX) Presents at Stifel 2024 Healthcare Conference (Transcript)

Stifel Nicolaus analyst Paul Matteis maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $4...

Vertex Pharmaceuticals (VRTX) Receives a Hold from Stifel Nicolaus

Analyst Geoff Meacham of Citi maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of $575.00. Ge...

Vertex Pharmaceuticals: Promising Growth with Suzetrigine Potential and Strategic Diversification

Scotiabank analyst Greg Harrison maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of $486.0...

Vertex Pharmaceuticals (VRTX) Receives a Hold from Scotiabank

AMGN

AXGN

BIIB

BNTX

CFLT

COCSF

CRSP

ELAN

FNKO

GILD

GOOG

GOOGL

GTLB

IDXX

INSG

IONS

MRNA

MSGS

NVSEF

PGNY

REGN

RHHBY

UHAL

ULCC

WFCNP

Screenshot 2024-09-30 at 9.13.36 PM

TNXP

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Press Releases

Vertex to Participate in Upcoming September Investor Conferences

Health Canada Grants Marketing Authorization of First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY® (Exagamglogene Autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Highlights First Oral Presentation of Phase 3 Clinical Data of the Vanza Triple and New Data on Long-Term Impact of TRIKAFTA® at the North American Cystic Fibrosis Conference

Vertex Announces Health Canada Acceptance of New Drug Submission for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-in-Class Triple Combination Treatment for Cystic Fibrosis

Entertainment

Real Estate

The Week in Canadian Press Releases: 10 Stories You Need to See

Vertex to Announce Third Quarter 2024 Financial Results on November 4th

Vertex to Present Phase 3 Data Highlighting Suzetrigine's Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists Annual Meeting

Vertex Provides Updates on Multiple Kidney Programs at the American Society of Nephrology (ASN) Annual Kidney Week Congress

Comments

Vertex Pharmaceuticals

空売り

Vertex Pharmaceuticals (NASDAQ:VRTX) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル